PTEN and prostate cancer: Moreover, the absence of ARPI benefit aligns with both preclinical studies and mCRPC clinical data which indicate that AVPC-TSG alterations may mediate resistance to hormonal treatments and docetaxel, with TP53, RB1, and PTEN loss driving prostate cancer progression and ARPI resistance.